one strongest quarter
time
earn well exceed expect sale signific
posit surpris japan guidanc recalibr
higher reflect signific out-performance
invest thesi invest debat revolv around abil
acceler ep growth maintain strong momentum japan turn
around us acceler pace capit manag follow
consid one strongest quarter compani mani
year expect investor optimist compani reach
inflect point pace growth set acceler quarter
sale japan well exceed expect follow highli success launch
new cancer product earn japan us also well exceed
expect although reflect expens time last manag
move guidanc higher although would note chang
expect forward estim least yet guidanc revis
pure reflect out-performance rel origin guidanc year-to-d
back result recalibr estim higher also
rais price target said reflect modest upsid
stock current trade chang equal-weight rate
stock
result report oper ep well ahead
estim consensu full year guidanc also
increas base averag rate
previous upsid quarter driven japan us japan
third sector sale significantli stronger expect although us
sale touch shi
estim higher ep estim increas
high end currency-adjust guidanc rang estim
increas tandem higher estim price target
stock also move higher
insur life/annu unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
base consensu methodolog
exhibit result compar expect
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
oper ep report oper ep well ahead
estim consensu full year guidanc also move
higher base averag rate previous
japan earn earn ran consider million ahead expect driven
lower expect benefit ratio versu prior estim
although part reflect impact exist policyhold upgrad
cancer polici new version combin expens larg in-lin
aggreg pre-tax profit margin came ahead prior estim
sale third sector product significantli stronger expect rise
reflect strong demand new cancer insur product introduc quarter
us earn earn ran million ahead expect benefit ratio
us higher expect versu prior expect
off-set lower expens reflect time issu rather level
sustain look forward
higher guidanc reflect upsid result first half year
manag revis higher ep guidanc base exchang
rate previous higher guidanc encourag
larg expect given out-performance saw first half year
manag guidanc remaind year point remain unchang
us sale sale growth ran touch shi rise versu expect
growth said would tend downplay import shortfal
sale increasingli skew fourth quarter
rais estim ep estim increas high
end currency-adjust guidanc rang estim increas
remain equal-weight rais price target stock
suggest modest upsid coupl view stock like ralli
back result chang current equal-weight rate
result compar expect
exhibit ep ahead expect consensu
japan came expect core benefit ratio run
favor expect
exhibit japan y/i chang benefit ratio
 earn similarli ran ahead sale weaker expect
new money yield remain pressur expect
valuat methodolog risk
valuat given aflac roe substanti peer stock
tend trade price-to-earn basi growth outlook remain
pressur see fair valu stock rang time
estim use ep estim would impli fair valu
price target equat time estim
stock current level view risk-reward balanc lead us equal-
risk currenc move interest rate weak us sale slower build japan
exhibit histor price book ex-aoci
exhibit histor price ntm earn
given aflac roe substanti peer
stock tend trade price-to-earn basi due
fluctuat yen see fair valu stock rang
time estim price target equat time
estim
japan third-sector sale growth acceler us sale also begin show
mid-to-high singl digit growth consist expens ratio us
japan come lower expect compani execut reinsur
transact free redund reserv japan allow increas
share repurchas yen continu strengthen
assum japan third sector sale grow us
assum growth expect margin japan
us close middl manag guidanc buyback
expect billion fx rate expect around
weaken yen us short-term interest rate move
japan increas cost maintain hedg program us
remain challeng unexpectedli weaker econom condit higher
expect expens ratio
invest debat revolv
around abil maintain impress
momentum third sector sale japan
reduc exposur volatil first
sector return us stronger
growth outlook manag
undertaken initi reinvigor growth
initi drive expens ratio
somewhat higher see mute near-
term growth potenti price target
yen earn highli sensit
 currenc rate yen sensit
sale japan sale exceed
expect face tough
comparison us sale begin
capit manag compani
expect buyback rang
billion said given significantli
higher stock price vs previou year see
level repurchas drive somewhat
macro develop notabl
chang exchang rate new
product offer japan
risk achiev price
currenc move interest rate weak
us result slow japan sale
price book ex-aoci
valuat methodolog risk associ price target rate recommend referenc
research report pleas contact client support follow us/canada hong kong
sydney tokyo altern may contact invest
repres morgan stanley research broadway attent research manag new york ny
